Humacyte Third Quarter 2026 Earnings Conference Call - HUMACYTE INC

Financial Performance:

• Third-quarter 2026 revenue reached $1.0 million, a 151% sequential increase from Q2 2026 ($0.4 million) and a 42% year-over-year increase from Q3 2025 ($0.7 million).
• Revenue for the nine months ended September 30, 2026, totaled $1.9 million, up from $1.0 million in the prior year period.
• Research and Development (R&D) expenses decreased to $14.1 million in Q3 2026 (vs. $17.3 million in Q3 2025) and $47.7 million for the nine-month period (vs. $54.7 million), driven by reduced non-commercial manufacturing runs.
• General and Administrative (G&A) expenses rose to $9.0 million in Q3 2026 due to a $0.6 million legal reserve for shareholder litigation settlement.
• Net loss for Q3 2026 was $15.5 million, a reduction from $17.5 million in the prior year quarter, primarily due to lower R&D; however, net loss for the nine-month period increased to $70.0 million due to non-cash remeasurement of contingent earn-out liabilities.
• Cost of Goods Sold (COGS) was $1.4 million in Q3 2026, with $0.8 million attributed to overhead from unused production capacity.
• Net cash used in operating activities was $15.0 million for Q3 2026, down from $23.9 million in the prior year quarter, reflecting cost reduction measures and lower inventory costs.
• The company held $64.9 million in cash, cash equivalents, and restricted cash as of September 30, 2026.

Guidance and Future Outlook:

• Fourth-quarter 2026 sales are projected to at least double Q3 results, driven by momentum and new hospital adoption.
• The Supplemental Biologics License Application (SBLA) for ATEV in dialysis access is scheduled for submission in November 2026.
• FDA filing acceptance is anticipated in January 2027; a Priority Review designation is expected but not guaranteed.
• Potential PDUFA dates are estimated for May 2027 (with Priority Review) or September 2027 (without), with commercial launch expected shortly thereafter (June or later in the year).
• Management expects positive gross margins to become sustainable in 2027 as production capacity utilization increases, though Q4 2026 will likely continue to include unused capacity overhead.
• Strategic focus for 2027 includes expanding the commercial footprint and maintaining robust production schedules to prevent stockouts.

Business Segments and Product Lines:

• SimVest (SynVest): Sales grew 44% in hospital adoption, increasing from 34 to 49 hospitals by September 30, 2026. October 2026 sales hit $800,000. The product is being adopted across trauma centers and vascular surgery practices.
• ATEV (Dialysis Access): Submission of SBLA supported by Phase III data (VO7 and VO12 studies) showing improved functional access and reduced catheter time compared to AV fistulas, particularly in women.
• CTEV (Coronary Artery Bypass Grafting): Phase IIa clinical study initiated in October 2026 with patient screening underway; FDA accepted the IND application.
• Vascular Trauma: Active expansion into trauma centers, with usage patterns shifting from planned surgeries to emergency trauma cases as surgeon confidence grows.
• Biovascular Pancreas: Remains a pipeline project; current focus is on benchtop work and a pending publication on primate islet survival, with resources to be prioritized in 2027 pending cash flow visibility.

Market and Competitive Landscape:

• The U.S. dialysis market represents a $2–3 billion annual opportunity, with 100,000 new patients entering dialysis annually.
• ATEV is positioned as the first major advancement in dialysis access in decades, targeting a specific demographic of women and men at risk for AV fistula non-maturation.
• CTEV is the first off-the-shelf conduit introduced for CABG studies in the U.S. in 40 years, offering an alternative to saphenous vein grafts.
• International expansion is underway with an MAA application under active review in Israel, and additional opportunities are being explored in the Middle East.

Risks and Challenges:

• Regulatory Uncertainty: The timeline for FDA approval depends on the granting of Priority Review; failure to secure this could delay PDUFA to September 2027.
• Production Capacity: High fixed costs associated with unused manufacturing capacity continue to inflate COGS and impact gross margins in the near term.
• Litigation: A $0.6 million reserve was established for a shareholder litigation settlement, contributing to G&A expenses.
• Adoption Friction: Surgeons require a learning curve and experience with the product in elective settings before utilizing it for emergency trauma or complex dialysis access cases.

Management Commentary and Tone:

• Management expressed high confidence, characterizing the quarter as an "inflection point" for the company following a comprehensive commercial team overhaul.
• CEO Dr. Laura Nicholson emphasized the transformative potential of the biologic solutions, citing significant momentum in both commercial sales and pipeline advancement.
• CFO Dale Sander highlighted the success of cost-reduction measures and the strategic shift in production scheduling to improve future margins.
• The tone was optimistic regarding 2026 year-end performance and 2027 growth, with a focus on "saving lives and limbs."

Analyst Questions and Answers:

• Commercial Durability: Management attributed the Q3 sales spike to the hiring of a specialized vascular surgery leadership team, refined marketing messaging, and introductory pricing strategies that lowered barriers for hospital adoption.
• Pricing & Margins: The list price for SimVest is approximately $17,000/unit, though ASP varies due to introductory pricing; ASP is expected to strengthen as adoption solidifies. Gross margins are not expected to turn positive in Q4 2026 due to production overhead but are forecast for improvement in 2027.
• Dialysis Launch Strategy: Leveraging existing relationships with vascular surgeons (who perform both trauma and dialysis access) to accelerate adoption; new nephrology advisors (Dr. Roy Chowdhury and Dr. Robert Kosman) are aiding in reimbursement modeling and value-based care alignment.
• Data Publications: Phase III VO12 data is being submitted to major vascular surgery journals, with long-term VO7 results also planned for publication prior to FDA approval.

Other Key Points:

• The company has hired Dr. Todd Rasmussen as Chief Surgical Officer to drive proactive medical education and surgeon training, creating a "virtuous cycle" of improved outcomes and adoption.
• Real-world evidence and case studies are being collected, with multiple presentations planned for the Vascular Endovascular Surgery (VESS) meeting in New York.
• The manufacturing facility has achieved high success rates, running 9–10 consecutive lots without failure, which is critical for future production scaling.
• The company is actively building financial models to demonstrate cost savings to Value-Based Care organizations focused on the "Optimal Start" metric for dialysis patients.